-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 5, Tibet Pharmaceuticals announced that for the new coronavirus pneumonia, the new crown vaccine products developed by the microorganisms involved in the cooperation based on its mRNA technology platform have been approved for clinical trials of the drug and will proceed with clinical trials as planned.
based on vaccine research and development experience, clinical trial research has some risks.
The progress and results of clinical trials are affected by, but are not limited to, trial scenarios, subject recruitment, outbreak development, and may be terminated due to issues such as the safety and/or effectiveness of clinical trials.
in response to this new coronavirus pneumonia, the microbiome launched an emergency research and development project on the new coronary mRNA vaccine in January 2020 and completed the pharmacodynamic study of all candidate vaccines.
, the vaccine has been clinically approved in China and clinical trials will be conducted as planned, overseas related work has not yet started, overseas declaration, registration, review, product launch in accordance with local laws and regulations.
In accordance with the agreement, the Company has paid an advance payment of RMB 35 million (including tax) after the signing of the agreement, and rmb 35 million (including tax) will be paid to the microorganisms after obtaining the Pharmaceutical Clinical Trial Approval.
。